Policy Impact: Sarcopenia is highly prevalent in older inpatients. Polypharmacy seems to be related to sarcopenia, and this finding deserves further study.Practice Impact: The finding that sarcopenia is highly prevalent in older inpatients suggests that geriatricians should pay more attention to its identification, prevention and treatment. The assessment of polypharmacy is particularly important in older patients with sarcopenia.IntroductionSarcopenia is a geriatric syndrome that is characterised by age‐related loss of muscle mass, muscle strength and muscle function . Sarcopenia has been associated with many negative health outcomes among older adults, such as a decline in functional status, falls, poor quality of life and increased mortality . Therefore, sarcopenia is of increasing interest to geriatricians and researchers. Recently, sarcopenia was assigned the new ICD‐10‐CM (M62.84) code, and this has been considered to represent ‘a major step forward in recognising sarcopenia’ .The diagnostic criteria for sarcopenia are still widely debated . More than six major diagnostic criteria and screening tools for sarcopenia are currently available . Among them, diagnostic strategies for sarcopenia from the European Working Group on Sarcopenia in Older People (EWGSOP) and Foundation for the National Institutes of Health Sarcopenia project are the most widely used. For studies conducted in
Australasian Journal on Ageing – Wiley
Published: Jan 1, 2018
Keywords: ; ; ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.
Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.
It’s easy to organize your research with our built-in tools.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera